Images List Premium Download Classic

Steatohepatitis

Steatohepatitis-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Systems, devices and methods for performing medical procedures in the intestine
Fractyl Laboratories, Inc.
July 12, 2018 - N°20180193590

A method for performing a medical procedure in an intestine of a patient is provided. The method comprises providing a system comprising: a catheter for insertion into the intestine, the catheter comprising: an elongate shaft comprising a distal portion; and a functional assembly positioned on the shaft distal portion and comprising at least one treatment element.
Mammalian glucosidase inhibitors, methods for their use and pharmaceutical compositions thereof
The University Of British Columbia
July 12, 2018 - N°20180193413

Provided are methods, uses and pharmaceutical compositions for inhibition of mammalian alpha-amylase in a subject, with a helianthamide peptide or a derivative thereof in a biologically effective amount. The subject in need of alpha-amylase inhibition, may have or be at risk of developing one or more of the following: middleton syndrome; a motility disorder of the gastrointestinal tract; postprandial reactive ...
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Novel composition for nonalcoholic fatty liver disease (nafld)
Cadila Healthcare Limited
July 05, 2018 - N°20180185330

The present invention provides a compound of formula (i) or pharmaceutical acceptable thereof, wherein ‘r’ is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (i) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (nafld) including fatty liver (steatosis), nonalcoholic steatohepatitis (...
Compositions and methods for the reduction or prevention of hepatic steatosis
Nusirt Sciences, Inc.
June 21, 2018 - N°20180169043

Methods useful for reducing or preventing non-alcoholic steatohepatitis or hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or pde5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof.
Non-alcoholic fatty liver disease biomarkers
The Regents Of The University Of California
June 07, 2018 - N°20180155787

Methods, compositions, kits, and systems for characterizing the non-alcoholic fatty liver disease (nafld) state of a subject are provided. In some embodiments the methods, compositions, kits, and systems comprise at least one mirna selected from the differentially expressed mirnas listed in at least one of tables 1-4, 10-14, and 28-29.
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Method for screening pharmaceuticals for treatment of steatohepatitis using n-terminal dimerization of apoptosis signal-regulated kinase1
Wuhan University
May 31, 2018 - N°20180149638

A method for screening a pharmaceutical compound for prevention, alleviation and/or treatment of steatohepatitis, the method including employing n-terminal dimerization of an apoptosis signal-regulated kinase 1 as a target.. .
Use of (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazine-3-yl)(naphthalene-2-yl) methanone in the prevention ...
Pierre Fabre Medicament
May 24, 2018 - N°20180140609

The present invention relates to (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazine-3-yl)(naphthalen-2-yl)methanone or one of the salts thereof, pharmaceutically acceptable for use in the prevention and/or treatment of hepatic steatosis, including non-alcoholic steatohepatitis or one of the complications of same.. .
Compositions, methods of treatment and diagnostics for treatment of hepatic steatosis alone or in combination ...
Volant Holdings Gmbh
May 10, 2018 - N°20180125870

The present invention is directed to pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of an array of the manifestations of metabolic syndromes, including type 2 diabetes, hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states that lead to these manifestations, among others. In additional aspects, the ...
Treatment for hepatic fibrosis
Galmed Research And Development Ltd.
May 10, 2018 - N°20180125862

The invention relates to the treatment and reduction of fibrosis, specifically hepatic fibrosis. More specifically, embodiments of the invention provide compositions and methods useful for the treatment and inhibition of hepato-fibrotic conditions associated with non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash), employing the use of 3β-arachidylamido-7α,12α-dihydroxy-5β-cholan-24-oic acid (...
Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
Askat Inc.
May 10, 2018 - N°20180125832

This invention is directed to prostaglandin e2 receptor 4 (ep4) antagonists useful in the treatment of nonalcoholic steatohepatitis (nash)-associated liver cancer in a human or animal. The method comprises administering one or more of compound a, compound b or compound c, or pharmaceutically acceptable salts thereof, as the ep4 antagonist(s).
Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2,4-diones for treatment of medical ...
Deuterx, Llc
May 03, 2018 - N°20180117026

The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the combination therapy.. .
Methods of treating liver disease using indane acetic acid derivatives
T3d Therapeutics, Inc.
May 03, 2018 - N°20180117013

This invention describes the use of indane acetic acid derivatives which are dual ppar delta/gamma agonists for the treatment of liver diseases including one or more of the following: nafld (non alcoholic fatty liver disease), nash (non alcoholic steatohepatitis), farber's disease, aclf (acute-on-chronic liver failure), clf (chronic liver failure), polt-hcv-svr (post-orthotopic liver transplant due to hepatitis c virus infection ...
Steatohepatitis Patent Pack
Download + patent application PDFs
Steatohepatitis Patent Applications
Download + Steatohepatitis-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Steatohepatitis-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Use of structurally enhanced fatty acids containing sulphur for preventing and or treating non alcoholic ...
Pronova Biopharma Norge As
April 19, 2018 - N°20180104201

The present disclosure relates to a method of preventing and/or treating non-alcoholic steatohepatitis in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a compound of formula (ii): wherein r1, r2, r3, x and y are as defined in the specification; or a pharmaceutically acceptable salt, solvate, or solvate of such a salt. ...
Method for discriminating symptom of hepatic disease
Sumitomo Dainippon Pharma Co., Ltd.
April 12, 2018 - N°20180100867

Provided is a noninvasive method for determining the presence of a symptom of a hepatic disease such as nonalcoholic fatty liver disease with a higher diagnostic accuracy. A method for discriminate between nonalcoholic fatty liver (nafl) and nonalcoholic steatohepatitis (nash), the method comprising: (1) a step of measuring the quantities of marker molecules contained in blood collected from a subject; (2) a ...
Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of ...
Volant Holdings Gmbh
April 12, 2018 - N°20180099001

The present invention is directed to a system characterization of nash that combines modeling and biomarkers, enabling pharmaceutical compositions and methods of treatment that relate to the inhibition, resolution and/or prevention of non alcoholic fatty liver disease (nafld) and non alcoholic steatohepatitis (nash). Said conditions are liver related complications among the array of manifestations of metabolic syndromes, including type 2 ...
Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor ...
Remd Biotherapeutics, Inc.
March 22, 2018 - N°20180079820

The present disclosure relates to methods for treating or preventing obesity and/or nonalcoholic fatty liver diseases (naflds) and/or nonalcoholic steatohepatitis (nash) using a glucagon receptor blocking agent. In various embodiments, the present disclosure relates to methods for treating or preventing nafld/nash using antigen binding and antagonizing proteins, e.g., fully human antibodies, that specifically bind to and ...
Computerized optical analysis methods of mr (magnetic resonance) images for quantifying or determining liver lesions
Centro De Investigacion Biomedica En Red (ciber)
February 22, 2018 - N°20180052213

A method computerized optically analyzes methods of conventional, preferably non-contrast-enhanced, mr (magnetic resonance) images of the liver. The method enables the detection of steatohepatitis by nash-mri and significant fibrosis by fibro-mri in patients suffering from nafld.
Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated ...
Vanderbilt University
February 22, 2018 - N°20180050083

The present invention relates to compositions and methods for treating diseases associated with dyslipidemia, including hypercholesterolemia, hypertriglyceridemia, steatohepatitis, atherosclerosis, obesity, hyperglycemia, metabolic syndrome, and related aspects of and conditions associated with metabolic syndrome. The compositions and methods disclosed herein are useful for regulating the lipid balance (lipid homeostasis) in a subject.
Methods and compositions for identifying non-alcoholic fatty liver disease
The Regents Of The University Of California
February 01, 2018 - N°20180031585

The disclosure provides methods for differentiating between non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. The method includes measuring eicosanoids and fatty acid levels in a biological sample..
Deuterated chenodeoxycholic acid derivative and pharmaceutical composition comprising compound thereof
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
February 01, 2018 - N°20180030083

Disclosed are deuterated chenodeoxycholic acid derivatives and pharmaceutical compositions containing the deuterated chenodeoxycholic acid derivatives. In particular, disclosed is a deuterated chenodeoxycholic acid derivative of formula (i), or a crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutical composition containing the same.
Loading